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Autoimmune hemolytic anemia (AIHA) occurs when pathogenic autoantibodies against 
red blood cell (RBC) antigens are generated. While the basic disease pathology of AIHA 
is well studied, the underlying mechanism(s) behind the failure in tolerance to RBC auto-
antigens are poorly understood. Thus, to investigate the tolerance mechanisms required 
for the establishment and maintenance of tolerance to RBC antigens, we developed a 
novel murine model. With this model, we evaluated the role of regulatory T cells (Tregs) in 
tolerance to RBC-specific antigens. Herein, we show that neither sustained depletion of 
Tregs nor immunization with RBC-specific proteins in conjunction with Treg depletion led 
to RBC-specific autoantibody generation. Thus, these studies demonstrate that Tregs 
are not required to prevent autoantibodies to RBCs and suggest that other tolerance 
mechanisms are likely involved.
Keywords: tolerance, autoimmunity, autoimmune hemolytic anemia, regulatory T cells, red blood cell, 
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inTrODUcTiOn
Loss of humoral tolerance to red blood cell (RBC) antigens may lead to development of pathogenic 
autoantibodies and result in autoimmune hemolytic anemia (AIHA) (1). When this occurs, it can 
have devastating effects. Immunosuppression can be efficacious, but many patients relapse within 
1-year post-treatment (2–4). Transfusion support of AIHA patients can be challenging, as many 
RBC autoantigens are common to essentially all RBC donors; thus, transfusable units may be limited, 
and in some cases, no compatible RBCs are available to transfuse. While the clinical presenta-
tion of AIHA has been well described, the basic pathogenesis of primary AIHA remains poorly 
understood (5).
Tolerance to autoantigens is achieved through a coordinated effort between central and peripheral 
tolerance mechanisms (6–8). Central tolerance is the education of developing B and T lymphocytes 
to autoantigens; self-reactive lymphocytes undergo deletion, receptor editing, anergy, or persist in 
a regulatory capacity. Although most self-reactive cells are eliminated centrally, some autoreac-
tive lymphocytes escape tolerance and persist and then mature in the periphery (9–11). However, 
unwanted activation of peripheral autoreactive cells is typically prevented by peripheral tolerance 
mechanisms, including regulatory cells, immunosuppressive cytokines, and antigen-presenting cells 
with tolerizing phenotypes (12, 13).
Abbreviations: AIHA, autoimmune hemolytic anemia; CFA, complete Freund’s adjuvant; HEL, hen egg lysozyme; HOD, trans-
genic mouse that expresses RBC-specific transgene HEL-OVA-Duffy; IMC, isotype-matched control; mIg-APC, anti-mouse Ig 
conjugated to APC; OVA, ovalbumin; RBC, red blood cell; Tregs, regulatory T cells.
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Despite multiple checkpoints to ensure tolerance to self-antigens, 
worldwide prevalence of autoimmunity is ~12%, indicating 
tolerance mechanisms break down (14). Moreover, RBC-specific 
autoantibodies are detectable in 0.1% of asymptomatic blood 
donors, suggesting that tolerance to RBC autoantigens frequently 
fail. Thus, to elucidate mechanisms of tolerance to RBC antigens and 
identify which tolerance pathways fail thereby leading to autoim-
munity, we have developed a model of RBC autoimmunity using 
the HEL–OVA–Duffy (HOD) mouse. The HOD mouse expresses 
a triple fusion protein consisting of hen egg lysozyme (HEL), oval-
bumin (OVA), and Duffy (HEL–OVA–Duffy) expressed behind an 
RBC-specific promoter (15). The HOD antigen is detected on RBC 
precursors and is expressed at levels comparable to naturally occur-
ring RBC antigens (16, 17). Using the HOD model, we previously 
reported that HOD mice are profoundly tolerant to both HOD RBCs, 
and also HEL and OVA protein-based immunizations. In mice 
expressing the HOD transgene, autoreactive HOD-specific T cells 
are detectable in the periphery, but are non-functional, as indicated 
by lack of T cell proliferation or activation upon stimulation with 
cognate antigen. However, HOD-reactive T cells function normally 
if they develop in the absence of the HOD antigen (e.g., wild-type 
mice). Unlike T cells, HOD autoreactive B cells survive central and 
peripheral tolerance in HOD transgenic mice and are fully capable 
of maturing into autoantibody-secreting plasma cells after receipt 
of functional autoreactive HOD-reactive T cells (through adoptive 
transfer). Thus, the HOD system identifies T cell anergy, or non-
responsiveness, as a critical checkpoint in the prevention of AIHA.
Regulatory T cells (Tregs) play a major role in tolerance to 
self-antigens, as congenital absence or transient depletion of 
Tregs has been correlated with early onset autoimmunity (18). 
A principle characteristic of Tregs is that they are unresponsive 
to T cell receptor stimulation and they can render other T cells 
anergic through immunosuppressive cytokine secretion or altera-
tion of the availability of IL-2, a cytokine essential for prolifera-
tion (19–21). While a lot is known about Tregs and their role in 
tolerance and autoimmunity, very little has been published on 
the relationship between Tregs and RBC-specific autoimmunity. 
Recently, Mqadmi et  al. (22) utilized a model in which AIHA 
is induced in mice by repeated transfusion of rat RBCs; in this 
model, Tregs were essential to mitigate autoimmunity. To build 
on these studies, we utilized a fully murine system (no xeno-
antigenic stimulus) and tested the requirement of Tregs in the 
establishment and maintenance of tolerance to a model antigen 
expressed on RBC precursors in the bone marrow and present 
throughout development and maturation of lymphocytes. In our 
model, sustained depletion of Tregs, or immunization with RBC-
specific proteins following Treg depletion each failed to induce 
autoimmunity. Together, these data demonstrate that Tregs are 
a non-essential component of tolerance against RBC-specific 
antigens and suggest that other mechanisms are involved.
MaTerials anD MeThODs
Mice
C57Bl/6 (B6) mice were purchased from NCI. B6.HOD (HOD) 
transgenic mice were generated as previously described and bred 
in the BloodworksNW vivarium (15, 23). Mice were maintained 
on standard rodent chow and water in a light- and temperature-
controlled environment. B6 and HOD mice were used at 
8–12 weeks of age and all procedures were performed according 
to protocols approved by the Bloodworks Northwest Institution 
Animal Care and Use Committee (IACUC).
Treatment of Mice
B6 and HOD recipient mice were treated weekly with an intra-
peritoneal (i.p.) injection of 300 μg of anti-CD25 (BioXcell, clone 
PC-61) or anti-HRPN Rat IgG1 isotype control (BioXcell). In 
some experiments, recipient mice were immunized subcutane-
ously with 100 μg of ovalbumin (Sigma) emulsified in CFA (Difco 
Labs). Sera were collected 14 days post-treatment.
Mhcii Tetramer-Based enrichment  
of antigen-specific endogenous  
cD4+ T cells
Leukocytes were harvested from spleen and lymph nodes, 
stained with pooled tetramer reagents, positively enriched, and 
stained with antibodies against cell surface markers as previ-
ously described (17). PE-conjugated tetramers utilized were: 
OVA329-337 (AAHAEINEA), OVA328-337 (HAAHAEINEA), 
and OVA325-335 (QAVHAAHAEIN). In some experiments, 
enriched leukocytes were stained with antibodies against CD25 
(clone PC-61 or 7D4), GITR, and PD1 (eBioscience). Intracellular 
FoxP3 staining was performed as suggested by the manufacturer 
(eBioscience). To assess for viability, cells were stained with 
AmCyan viability dye (eBioscience).
antibody Detection
Flow crossmatch, direct antiglobulin test (DAT), and determina-
tion of anti-OVA antibodies (by ELISA) were performed as previ-
ously described (24, 25). To assess for HOD antigen expression, 
RBCs were stained with monoclonal antibodies specific for HEL 
(4B7) and Duffy (MIMA-29), as previously described (15, 17).
statistics
Significance was determined with a Student’s T-test for experi-
ments with two groups or one-way ANOVA with a Bonferroni 
post-test for experiments with three or more groups. Significance 
was set at p < 0.05.
resUlTs
endogenous autoreactive cD4+ T cells in 
hOD Mice express regulatory Markers
To test the hypothesis that Tregs are required for prevention 
of RBC-specific autoantibodies, we utilized the HOD mouse 
model; as previously described, the RBC-restricted HOD antigen 
contains a triple fusion protein consisting of HEL, OVA, and 
human blood group molecule, Duffy (15). In our previous stud-
ies, we utilized MHCII tetramer reagents to detect RBC-specific 
T cells, specifically OVA-reactive CD4+ T cells (17); since our 
initial report, we have broadened our antigen coverage through 
implementation of an additional MHCII tetramer reagent. Thus, 
the current studies utilize pooled tetramer reagents for peptides 
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OVA329-337 (AAHAEINEA), OVA328-337 (HAAHAEINEA), 
and OVA325-335 (QAVHAAHAEIN). To compare the number 
of endogenous CD4+ T cells that recognize OVA within both 
HOD and control B6 mice, we performed MHCII tetramer-based 
enrichments with pooled tetramer reagents. Enriched leukocytes 
were subsequently stained with antibodies against surface 
antigens CD3, CD4, CD8, CD19, CD11c, F4/80, and CD11b to 
delineate T cell populations. CD4+ T cell populations, defined as 
CD4+CD3+CD8−CD19−CD11c−F4/80−CD11b− were sub-
sequently assessed for binding to OVA tetramers. To determine 
background staining for pooled OVA tetramers, CD4+ T cells 
that were not enriched were assessed for tetramer staining (Figure 
S1 in Supplementary Material). Evaluating the enriched CD4+  
T cell population, as previously reported, B6 and HOD mice have 
similar absolute numbers of endogenous OVA-reactive CD4+  
T cells (Figure 1A); however, pooling 3 MHCII tetramer reagents 
resulted in higher overall numbers (mean B6: 103; HOD: 109) 
than previously reported with only two tetramers (mean B6: 40; 
HOD: 56), suggesting that additional OVA-reactive CD4+ T cells 
can now be identified (17).
We previously observed that autoreactive endogenous OVA-
specific CD4+ T cells in HOD mice do not respond to their 
cognate antigen and are non-functional; thus, it is plausible that 
these cells are Tregs or are under regulatory control exerted by 
Tregs. To test whether these OVA-reactive CD4+ T cells are 
Tregs, cells were co-stained for CD25 and FoxP3. Compared to 
control B6, HOD mice had a slightly higher, but not statistically 
significant, percentage of CD25+FoxP3+CD4+ T cells, a pheno-
type consistent with Tregs (Figure 1B). Moreover, the frequency 
of OVA-reactive CD4+ T cells that also expressed PD1 was 
significantly higher in HOD mice when compared to control B6 
(Figure 1C). Representative dot plots of PD1 expression within 
OVA-tetramer reactive CD4+ T cells for both B6 and HOD are 
shown in Figure 1C left and middle, respectively. The frequency 
of PD1+OVA-reactive CD4+ T cells from all experimental mice is 
shown in graph form Figure 1C right. Additional analysis revealed 
that HOD mice had an elevated, but not significant, frequency of 
GITRhi+OVA-reactive CD4+ T cells in HOD mice (Figure 1D). 
Representative dot plots for B6 and HOD (Figure  1D left and 
middle) and frequencies from all experimental mice (Figure 1D 
right) are shown. Given that co-expression of CD25 and FoxP3, 
and both PD1 and GITR have all been associated with regulatory 
function of regulatory T cells (26, 27), these data suggest that a 
subset of autoreactive endogenous OVA-reactive CD4+ T cells 
in HOD mice express a phenotype that is consistent with Tregs.
Depletion of Tregs Does not lead to 
autoantibody generation
To test whether Tregs are required to prevent RBC-specific 
autoantibodies, B6 and HOD mice were treated with anti-CD25 
(clone PC-61), a regimen previously shown to deplete Tregs (26, 
28). Control cohorts received Rat IgG1 isotype-matched control 
(IMC). Treg depletion was evaluated 3  days post-treatment by 
staining with anti-CD25 clone 7D4, an antibody with specific-
ity for an epitope distinct from clone PC-61 (29). Anti-CD25, 
but not IMC, led to significant reduction in the percentage of 
CD25+CD4+ T cells and FoxP3+CD25+CD4+ Tregs, with 
similar frequencies detectable in both HOD and B6 mice 
(Figures  1E,F). Given that anti-CD25 monoclonal antibody 
may also affect other cell types that express CD25, total 
CD25+FoxP3−CD4+ effector T cells were also analyzed (30). 
Treatment with anti-CD25, but not IMC, led to a significant 
reduction of effector T cells in both HOD and control B6 mice 
(Figure  1G). Finally, there was a significant reduction in total 
CD4+ cells upon anti-CD25 treatment (Figure 1H).
To evaluate whether sustained depletion of Tregs led to anti-
RBC autoantibodies, mice were maintained on the anti-CD25 or 
IMC regimen for 4 weeks, after which endogenous numbers of 
OVA-reactive CD4+ T cells were enumerated and assessed for 
co-expression of CD25 and FoxP3. Prolonged treatment with 
monoclonal antibodies did not significantly affect the absolute 
numbers of detectable OVA-reactive CD4+ T cells in HOD or 
control B6 mice (Figure 2A). However, within the OVA-reactive 
CD4+ T cell population, the percentage of CD25+FoxP3+CD4+ 
Tregs was decreased in HOD animals treated with anti-CD25 
when compared to IMC (Figure  2B). Likewise, prolonged 
treatment with anti-CD25 or IMC did not significantly alter the 
percentage of CD25+FoxP3−CD4+OVA-reactive effector T cells 
(Figure 2C). Humoral responses post monoclonal antibody treat-
ment were also evaluated. Detection of RBC-specific antibodies 
was assessed by flow crossmatch. Briefly, sera from experimental 
mice were incubated with HOD or control B6 RBCs followed 
by staining with anti-mouse immunoglobulin secondary conju-
gated to APC (mIg APC). Neither control B6 nor HOD animals 
that received anti-CD25 or IMC made detectable anti-HOD 
antibodies (data not shown and Figure 2D). To assess whether 
autoantibodies were secreted but were binding directly to RBCs, 
RBCs from experimental mice were incubated with mIg APC, an 
assay known as a DAT. Neither B6 nor HOD mice had detectable 
antibodies bound to their RBCs (data not shown and Figure 2E). 
An alternate hypothesis is that HOD antibodies were produced in 
HOD mice, binding to HOD antigen, but were mediating antigen 
modulation. To test this hypothesis, RBCs from experimental 
HOD mice were stained with 4B7 (an anti-HEL monoclonal 
antibody) or MIMA-29 (an anti-Duffy monoclonal antibody) 
followed by mIg APC (17, 31). Naïve, anti-CD25-treated, and 
IMC-treated HOD animals had similar expression patterns of 
detectable HEL and Duffy on their RBC surface, demonstrating 
that antigen modulation had not occurred (Figures 2F,G). Taken 
together, a sustained absence of Tregs did not lead to autoanti-
body production in HOD or control B6 mice. Furthermore, these 
data suggest that Tregs are not required to prevent autoreactive 
endogenous OVA-reactive CD4+ T cells (within HOD mice) 
from activating.
Treg Depletion in conjunction with 
immunization Does not elicit 
autoantibodies in hOD Mice
Development of autoimmunity is postulated to require multiple 
hits, with each “hit” weakening tolerance mechanisms (32). 
To test whether immunization in the absence of Tregs leads to 
autoantibodies, B6 and HOD mice received anti-CD25 or IMC 
FigUre 1 | autoreactive OVa-specific cD4+ T cells in hOD mice express elevated levels of regulatory markers and can be depleted with anti-cD25 
monoclonal antibodies. (a) Endogenous numbers of OVA-specific CD4+ T cells in HOD and control B6 mice were determined by MHCII tetramer-based enrichment 
using pooled tetramers OVA329-337, OVA328-337, and OVA325-335. Data presented are gated on viable cells with phenotype CD4+CD3+CD8−CD19−CD11c− 
F4/80−CD11b−. (B–D) Enriched tetramer-binding T cells were evaluated for expression of regulatory T cell markers by staining for (B) surface CD25 (PC-61) and 
intracellular transcription factor FoxP3, (c) PD1, and (D) GITR. (e–g) To deplete CD4+CD25+FoxP3+ regulatory T cells, HOD and B6 mice were treated weekly 
with intraperitoneal doses of 300 μg of anti-CD25 monoclonal antibody (clone PC-61) or anti-HRPN Rat IgG1 isotype-matched control (IMC). Efficiency of depletion 
was evaluated 3 days post-treatment and frequencies of (e) CD25+CD4+ T cells, (F) FoxP3+CD25+CD4+ T cells, (g) CD25+FoxP3−CD4+ T cells, and (h) total 
CD4+ T cells were determined. Data shown are the cumulative results from three independent experiments with at least three mice per group.
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FigUre 2 | Tregs are not required to prevent rBc-specific autoimmunity. Control B6 and HOD mice were treated weekly for 4 weeks with 
intraperitoneal injections of 300 μg of anti-CD25 monoclonal antibody (PC-61) or anti-HRPN isotype-matched control (IMC). At the conclusion of treatment,  
(a) absolute numbers of endogenous OVA-reactive T cells were quantified, and the percentage of (B) CD25+FoxP3+CD4+ regulatory T cells and  
(c) CD25+FoxP3−CD4+ effector T cells were evaluated. (D) To evaluate autoantibody production, experimental serum was utilized for flow crossmatch 
analysis by incubation of serum with HOD target RBCs, followed by staining with an anti-mouse Ig secondary conjugated to APC (mIg APC). (e) To assess 
whether RBCs from experimental mice had autoantibodies bound to them, RBCs were stained with mIg APC. (F,g) To test for antigen modulation, 
experimental RBCs were assessed for expression of HOD antigen proteins by staining for (F) HEL with monoclonal antibody 4B7 and (g) Duffy with 
monoclonal antibody MIMA-29. In some experiments, experimental mice received a 100 μg OVA/CFA immunization at the midpoint of treatment with anti-CD25 
or IMC. (h) Expansion of OVA-binding T cells was evaluated by MHCII tetramer-based enrichment 2 weeks post-immunization. Data presented are gated on 
CD4+CD3+CD8−CD19−CD11c−F4/80−CD11b− cells. (i,J) Autoantibody production was assessed by flow crossmatch whereby serum from experimental 
mice was incubated with (i) control B6 and (J) HOD RBC targets followed by mIg APC. (K) Production of OVA-specific antibodies by experimental mice was 
evaluated by ELISA.
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for 4  weeks. At the midpoint of treatment, experimental mice 
received an OVA/CFA immunization. Mice were sacrificed 
2 weeks post-immunization and total endogenous OVA-reactive 
T cells were enumerated by MHCII tetramer-based enrichment. 
Significant expansion of endogenous OVA-reactive CD4+ T cells 
was observed in control B6 mice immunized with OVA/CFA 
(mean IMC: 1273; anti-CD25: 2379) (Figure 2H); however, there 
was no significant expansion in OVA/CFA immunized HOD 
animals, regardless of IMC or anti-CD25 treatment. To assess for 
production of HOD-specific antibodies, sera were analyzed by 
flow crossmatch against B6 and HOD RBC targets (Figures 2I,J). 
Sera from B6 but not HOD mice (both anti-CD25 and IMC-treated 
groups) made antibodies to the HOD antigen. Given that an OVA/
CFA injection into HOD mice failed to elicit OVA-specific T cell 
expansion and to promote HOD-specific antibody generation, we 
performed an OVA-specific ELISA to test the hypothesis that the 
OVA/CFA immunization was successful in HOD mice. By design, 
the HOD antigen only contains the C-terminal half of OVA (15). 
Thus, an OVA/CFA immunization with the whole OVA protein 
is postulated to elicit antibodies to both the C- and N-terminal 
regions of the protein. As such, an ELISA containing the whole 
OVA protein was utilized to evaluate the effectiveness of the OVA/
CFA immunization. OVA-specific IgG antibodies were detectable 
in both B6 and HOD mice that received an OVA/CFA immuniza-
tion, regardless of antibody treatment (Figure  2K), suggesting 
that HOD mice made OVA-specific antibodies to the N-terminal 
portion of OVA, which is not contained within the HOD antigen. 
Together, these data demonstrate that immunization in combina-
tion with Treg depletion is not sufficient to break down tolerance 
and lead to autoantibodies in HOD animals. It further suggests 
that neither RBC-specific Tregs nor immunosuppressive effects 
by Tregs are required to prevent anti-RBC autoantibodies.
DiscUssiOn
Failure of tolerance mechanisms to RBC antigens can lead to 
development of pathogenic autoantibodies, which can mediate 
destruction of RBCs and result in AIHA, a severe and sometimes 
fatal disease. Using the HOD mouse model, we have previously 
reported that tolerance to RBC self-antigens is incomplete in 
the B cell compartment; however, stringent T cell tolerance 
prevents RBC-specific autoreactive B cell activation and subse-
quent autoantibody production. One potential mechanism of 
T cell tolerance employed to prevent autoimmunity is through 
immunosuppression by Tregs (33, 34). As evidence of their 
immunosuppressive capabilities, in both human trials and 
murine models, transient depletion or functional inactivation of 
Tregs has been documented to be an effective strategy to enhance 
anti-tumor responses and treat chronic infections (35, 36). Given 
their potency, we hypothesized that Tregs were required for main-
tenance of tolerance to RBC-specific autoantigens. However, data 
presented herein suggest that Tregs are not essential to maintain 
tolerance to RBC autoantigens.
RBC-specific autoreactive T cells are detectable in HOD mice. 
However, these autoreactive CD4+ T cells are non-functional 
and co-express CD25 and FoxP3, a phenotype consistent with 
Tregs. Additional phenotypic characterization revealed that these 
autoreactive T cells express elevated levels of PD1 and GITR, 
surface markers associated both with regulation and exhaustion. 
Given that RBCs have a life span of ~50 days in the mouse (or 
~120 days in humans), and are continually renewed by the bone 
marrow, autoreactive T cells undergo chronic exposure to large 
amounts of RBC-derived antigens. Accordingly, T cells in our 
model express both regulatory and exhaustion cellular markers, 
a phenotype associated with T cells exposed to chronic cognate 
autoantigen. Functionally, T cells that encounter persistent anti-
gen may become anergic, which is characterized by inhibition of 
proliferation and effector functions. There are several categories 
of anergy, some of which can be reversed through cytokine 
exposure, providing costimulation, or removing autoreactive 
T cells into an environment that lacks their autoantigen (20). 
Aspects of anergy (e.g., lack of proliferation) are found in the Treg 
compartment as well, making it difficult to discern between the 
anergic states (10). However, phenotypic analysis suggested that 
HOD-specific autoreactive T cells could be Tregs.
Canonically, Tregs express high levels of surface CD25, a 
receptor that binds to proliferative cytokine IL-2. Through CD25 
expression, Tregs can mediate immune suppression through IL-2 
scavenging, thereby depriving other cells (e.g., T cells) of this 
proliferation-inducing cytokine and successfully dampening sub-
sequent immune responses (37). Targeting CD25 with monoclo-
nal antibodies has been an effective way to inhibit Treg function, 
which has provided insight into the mechanistic understanding 
of how Tregs modulate immune responses. Although the field 
remains divided upon the mechanism of action of anti-CD25 
antibodies (29, 38), data with our model (and others) suggest that 
monoclonal anti-CD25 treatment induced significant deletion of 
the CD25-expressing CD4+ T cells, both CD25+FoxP3+CD4+ 
Tregs and CD25+FoxP3−CD4+ effector T cells (30). While com-
plete depletion of CD25+FoxP3+CD4+ T cells is not achieved 
with this approach, over 75% of total Tregs became undetectable 
post anti-CD25 treatment; furthermore, OVA-specific Tregs, but 
not overall numbers, were reduced in anti-CD25 treated HOD 
mice. This treatment regimen has been documented to effectively 
result in inhibition of Treg function and is sufficient to promote 
autoantibody synthesis. However, upon treatment of HOD mice 
with anti-CD25 antibodies for 4 continuous weeks, no autoanti-
bodies were detected. Thus, these data suggest that prevention of 
RBC-specific autoantibody generation is not dependent upon the 
regulatory function of Tregs.
Initiation of autoimmune disease has been postulated to occur 
in response to or concurrent with infection or excessive immune 
activation in otherwise immunocompetent individuals. As such, 
a complex microbial history may play a role in the development of 
autoimmunity. Indeed, there is a higher frequency of autoimmun-
ity in the elderly, a population that has potentially encountered 
more pathogens, compared to younger age groups (39). Upon each 
pathogen encounter, the immune response may give rise to new 
cross-reactive lymphocytes, such that the lymphocyte can react 
to both foreign antigen and self-antigen. Furthermore, inflam-
mation elicited in response to pathogens may induce bystander 
activation of autoreactive cells. To test whether inflammation, in 
combination with an absence of immune regulation by Tregs, and 
exposure to cognate antigen could lead to autoantibodies, HOD 
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mice were treated with anti-CD25 and then immunized with 
OVA/CFA. CFA elicits a strong immune response, with copious 
TH1 cytokine production, including IL-2 (40). In control mice, 
robust proliferation of OVA-specific T cells was detected, whereas 
there was no significant expansion in HOD mice. Thus, even 
with a strong immune stimulus and lack of immunosuppressive 
cytokines, autoreactive HOD CD4+ T cells were still not capable 
of providing adequate help to B cells thereby adding support to 
our hypothesis that Tregs are dispensable for the prevention of 
RBC-specific autoreactive antibodies.
Anti-CD25 monoclonal antibody treatment targets not only 
CD25+FoxP3+ Tregs but also CD25+ effector T cells, which 
are critical to providing B cell help to elicit antibodies. Thus, it 
is plausible that anti-CD25 treatment would impact antibody 
production. However, in both B6 and HOD mice that received 
sustained antibody treatment in conjunction with an OVA/CFA 
immunization, anti-OVA antibody titers were similar between 
anti-CD25 and IMC groups, demonstrating that B cell received 
adequate help (Figure  2J). These data, in combination with 
Figure  2C demonstrating that OVA-reactive effector cells are 
not significantly affected by anti-CD25 treatment, suggest that 
despite significant reductions of CD25+ T cells, there are enough 
remaining effector cells to provide B cell help for antibody pro-
duction. Alternatively, effector T cells may stimulate anti-OVA 
antibody production in a CD25-independent fashion (41). 
Regardless of mechanism, while anti-CD25 treatment may affect 
cells that transiently express CD25, monoclonal antibody treat-
ment does not prevent antibody production in this model. Thus, 
given that anti-HOD antibodies are not detected in HOD animals 
treated with anti-CD25 and OVA/CFA, these data, in aggregate, 
suggest that other regulatory mechanisms besides Tregs play an 
important role in maintaining tolerance to RBC antigens.
In summary, our findings suggest that Tregs are not required 
for the prevention of RBC autoimmunity; however, we cannot 
rule out that Tregs may be involved, as multiple redundant toler-
ance pathways may be utilized to maintain tolerance to RBC anti-
gens. Indeed, establishment of T cell tolerance can be achieved 
through deletion, anergy, and regulation; thus, it is possible that 
multiple pathways are utilized for a specific antigen-reactive T cell 
population. These data suggest that, unlike most tissue-specific 
antigens, Tregs are not required for preventing the development 
of RBC-specific autoimmunity. However, the specific tolerance 
mechanisms employed against RBC-specific antigens is stringent 
and cannot be compromised by the absence of Tregs, even in the 
presence of strong immune activation. Taken together, these data 
suggest that other tolerance pathways are likely involved.
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Unenriched leukocytes were utilized to determine the background staining for 
OVA-specific MHCII tetramers. Leukocytes were gated on CD4+CD3+CD8− 
CD19−CD11c−F4/80−CD11b− and evaluated for OVA-tetramer binding and 
positive staining gate was drawn.
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